First Trust Nasdaq Pharmaceuticals ETF (FTXH) |
| 33.3912 -0.055 (-0.16%) 01-13 16:00 |
| Open: | 33.44 |
| High: | 33.56 |
| Low: | 33.3912 |
| Volume: | 1,864 |
| Market Cap: | 22(M) |
| PE Ratio: | 21.09 |
| Exchange: | NASDAQ Global Market |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 39.84 |
| Resistance 1: | 34.11 |
| Pivot price: | 33.37 |
| Support 1: | 32.70 |
| Support 2: | 31.83 |
| 52w High: | 34.108 |
| 52w Low: | 23.285 |
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 19 Nov 2025
Pharma ETF (FTXH) Hits New 52-Week High - Nasdaq
Sat, 15 Nov 2025
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs - Benzinga
Fri, 14 Nov 2025
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results - Zacks Investment Research
Thu, 16 Oct 2025
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook - TradingView — Track All Markets
Mon, 29 Sep 2025
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms - Benzinga
Fri, 26 Sep 2025
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit - The Globe and Mail
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
